Snowball logo
logo
METX

METXF

METXF • PINK
$1.67$0.00  (0%)
Estimate
EPS
-0.03
Beta
-0.039
Growth
Net income, YoY
-12.28%
FCF, YoY
-10.66%
About the company
Ticker
METXF
ISIN
Country
Canada
Sector (GICS)
Other
ME Therapeutics Holdings Inc., a preclinical stage biotechnology company, engages in the development of cancer fighting drugs in the field of immuno-oncology. The company's lead candidate, h1B11-12, is a glycoprotein cytokine antibody drug that targets a key protein involved in the generation of suppressive myeloid cells for the treatment of colorectal cancer. It also develops D094 and D099, which are small molecule myeloid targeted prodrug candidates to treat cancer; and myeloid targeting lipid nanoparticles (LNPS) formulations. ME Therapeutics Holdings Inc. was founded in 2014 and is headquartered in Vancouver, Canada.

Frequently asked questions

What sector does METXF (METXF) operate in?

METXF belongs to the Other sector and operates in the Biotechnology industry.

What is METXF (METXF) current stock price?

As of the latest data, METXF stock price is $1.67, with a previous close of $1.67.

What is METXF (METXF) current market capitalization?

METXF market cap is approximately 50.18 million.

What is METXF (METXF) Earnings Per Share (EPS)?

The trailing EPS is -$0.03.

Does METXF (METXF) pay dividends?

No. METXF does not pay a dividend.

What is METXF (METXF) beta (volatility) score?

METXF has a beta of -0.039, indicating lower volatility than the overall market.